Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› North Carolina
Clinical trial register · United States · industry-sponsored

Clinical Trials in North Carolina, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4438 Illinois 2485 Georgia 2364 Arizona 2242
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie35 AstraZeneca32 Novartis Pharmaceuticals23 Janssen Research & Development, LLC22 Hoffmann-La Roche18
State
California5299 Florida4438 Illinois2485 Georgia2364 Arizona2242
All 51 states
Target enrolment
to

Trials with a site in North Carolina

1082 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Autonomous Healthcare, Inc.
Not applicable
10
North Carolina
2027-03
Recruiting
Innoviva Specialty Therapeutics
Phase 1
48
California, North Carolina, Texas
2026-12-30
Recruiting
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
NCT07719608Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
Salvia BioElectronics
Not applicable
150
Georgia, Maryland, North Carolina
2026-12-01
Not yet open
Amgen
Phase 2
15
Florida, North Carolina, Pennsylvania
2026-10-31
Not yet open
T3D Therapeutics, Inc.
Phase 2/3
376
North Carolina
2026-10-26
Recruiting
Biogen
Observational
10
North Carolina
2026-10-26
Not yet open
Boehringer Ingelheim
Phase 3
600
Arizona, California, Florida, Kansas, New Mexico, North Carolina
2026-10-23
Not yet open
Novo Nordisk A/S
Phase 3
84
Iowa, Louisiana, Minnesota, Missouri, North Carolina, Oklahoma, Pennsylvania, Texas
2026-10-09
Not yet open
ModernaTX, Inc.
Phase 4
300
Kansas, Kentucky, North Carolina, Tennessee, Texas
2026-10-09
Not yet open
3-C Institute for Social Development
Not applicable
66
North Carolina
2026-10-01
Not yet open
Pfizer
Phase 3
660
Alabama, Florida, Kentucky, Michigan, Missouri, Montana, North Carolina, Ohio
2026-10-01
Not yet open
A Mobile Text Approach to Measurement and Feedback for Wraparound Care Coordination
NCT07300930Mental Health Services, Mobile Technologies, Technology Development
3-C Institute for Social Development
Not applicable
216
North Carolina
2026-10-01
Recruiting
TG Therapeutics, Inc.
Phase 2
120
Colorado, Florida, Michigan, North Carolina, South Carolina
2026-10-01
Not yet open
Callahan-Young LLC DBA Jigsawdio
Not applicable
80
North Carolina, Texas
2026-10
Recruiting
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
NCT07840326Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
Sundance Biosciences, Inc.
Phase 2
20
Georgia, North Carolina, Ohio
2026-10
Not yet open
Natera, Inc.
Not applicable
1,010
Alabama, California, Florida, Illinois, Minnesota, New York, North Carolina, Ohio
2026-10
Not yet open
SURGE Therapeutics
Phase 3
400
Minnesota, New York, North Carolina
2026-10
Not yet open
HeartFlow, Inc.
Not applicable
350
North Carolina
2026-10
Not yet open
Annexon, Inc.
Phase 3
605
Florida, Maryland, Massachusetts, North Carolina, Oregon
2026-09-30
Recruiting
Trevi Therapeutics
Phase 3
201
Delaware, Florida, North Carolina, Texas
2026-09-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,104
Florida, Maryland, North Carolina, South Carolina, Texas
2026-09-25
Recruiting
CRPS-RISE Outcomes Registry
NCT07811362Complex Regional Pain Syndrome I (CRPS I)
Ambros Therapeutics, Inc.
Observational
270
North Carolina
2026-09-17
Recruiting
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
Good Molecules, LLC
Phase 4
60
North Carolina
2026-09-14
Recruiting
Clinical Outcomes of 3D Printed and Milled Complete Dentures
NCT07586774Edentulous Mouth, Edentulous Jaw
Dentsply Sirona Implants and Consumables
Not applicable
68
North Carolina
2026-09-11
Recruiting
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
GlaxoSmithKline
Phase 1/2
184
California, North Carolina, Ohio
2026-09-09
Not yet open
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
Recruiting
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, Minnesota, North Carolina, Texas
2026-09-01
Recruiting
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder
NCT07282678Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Pulvinar Neuro, LLC
Not applicable
214
North Carolina
2026-09
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 3
30
North Carolina
2026-09
By invitation
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
NCT07197788Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Not applicable
50
Florida, Massachusetts, New Jersey, North Carolina, Texas
2026-09
Not yet open
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
NCT06534502Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial
Azurity Pharmaceuticals
Phase 4
40
North Carolina, Tennessee
2026-09
Recruiting
Rapport Therapeutics Inc.
Phase 3
312
Alabama, Arkansas, Colorado, Florida, Illinois, New York, North Carolina, Tennessee
2026-09
Recruiting
IDEAYA Biosciences
Phase 3
450
Arizona, California, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
California, Georgia, Massachusetts, North Carolina, Ohio, Texas
2026-09
Not yet open
Trial of NASHA Dx Urethral Bulking System
NCT07850804Urinary Incontinence, Urinary Incontinence (UI), Urinary Incontinence , Stress, Urinary Incontinence Due to Urethral Sphincter Incompetence
Palette Life Sciences, Inc.
Not applicable
314
California, Nebraska, North Carolina, Pennsylvania, Texas
2026-09
Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 3
160
Nevada, North Carolina, Texas
2026-08-31
Recruiting
Pfizer
Phase 3
440
California, District of Columbia, Georgia, New York, North Carolina, Pennsylvania
2026-08-31
Recruiting
MBX Biosciences
Phase 3
160
Florida, Louisiana, Nevada, New York, North Carolina, South Carolina, Texas, Washington
2026-08-26
Recruiting
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
NCT07765446Chemotherapy-induced Peripheral Neuropathy
Sironax USA, Inc.
Phase 2
18
Florida, Maryland, Massachusetts, New Jersey, North Carolina
2026-08-21
Recruiting
Pfizer
Phase 3
1,100
California, Florida, Maryland, New Jersey, North Carolina, Texas
2026-08-20
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08-18
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
260
Indiana, New York, North Carolina, Ohio, Texas
2026-08-17
Recruiting
Alkermes, Inc.
Phase 3
150
Florida, Georgia, Michigan, Missouri, North Carolina, Ohio, South Carolina, Texas
2026-08-13
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
AbbVie
Phase 1
120
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
Recruiting
Janssen Research & Development, LLC
Phase 4
10
North Carolina
2026-08-07
Recruiting
Sanofi
Observational
350
Indiana, North Carolina, Texas
2026-08-06
Recruiting
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan, North Carolina
2026-07-30
Recruiting
Biogen
Phase 2
60
Arizona, California, Florida, Maryland, New Jersey, North Carolina, Texas, Virginia
2026-07-30
Recruiting
Ipsen
Observational
3
North Carolina
2026-07-29
Recruiting
Arvinas Inc.
Phase 1/2
499
North Carolina, Texas, Virginia
2026-07-29
Recruiting
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, North Carolina
2026-07-28
Recruiting
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III
DrugFT819
Fate Therapeutics
Phase 2
53
California, Florida, Nebraska, North Carolina, Texas
2026-07-27
Recruiting
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
36
California, Colorado, Georgia, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
BioNTech SE
Phase 4
200
California, Florida, Hawaii, North Carolina, Utah
2026-07-23
Active, closed
AbbVie
Phase 2
84
California, New York, North Carolina, Texas
2026-07-22
Recruiting
GlaxoSmithKline
Phase 3
380
Arkansas, California, Florida, Missouri, New York, North Carolina, Ohio, Texas
2026-07-22
Recruiting
Freya Biosciences ApS
Phase 2
30
Kansas, Massachusetts, North Carolina, Texas
2026-07-22
Recruiting
Kinaset Therapeutics Inc
Phase 2
512
California, Florida, Illinois, Missouri, North Carolina, Pennsylvania, South Carolina, Texas
2026-07-16
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New York, North Carolina, Oklahoma
2026-07-16
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Arkansas, California, Florida, Illinois, Indiana, Nebraska, New York, North Carolina
2026-07-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
7,050
Alabama, Arizona, Arkansas, California, Florida, Indiana, Louisiana, North Carolina
2026-07-10
Recruiting
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
NCT07758140HPV, HPV - Anogenital Human Papilloma Virus Infection
Mel Mont Medical
Not applicable
260
Arizona, California, Florida, Idaho, Montana, North Carolina, Texas, Washington
2026-07-09
Recruiting
Jazz Pharmaceuticals
Phase 3
120
Alabama, California, Colorado, Florida, Georgia, North Carolina, Ohio, Tennessee
2026-07-09
Recruiting
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Recruiting
A Usability Study of a Multi-channel ECG Monitoring Device
NCT07388355Healthy Adult Participants, Heart Disease, Arrythmia, Cardiac
Wearlinq
Not applicable
500
North Carolina
2026-07-06
Not yet open
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
Neuvosyn Laboratories, LLC
Phase 3
466
California, Colorado, Florida, Idaho, Massachusetts, Nevada, North Carolina, South Carolina
2026-06-30
Active, closed
Boehringer Ingelheim
Phase 2
344
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
Dianthus Therapeutics
Phase 3
195
California, Florida, North Carolina, Texas
2026-06-29
Recruiting
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Louisiana, Missouri, North Carolina, Pennsylvania, South Carolina
2026-06-29
Active, closed
Moonlight Therapeutics, Inc.
Phase 1
40
Arkansas, Georgia, Kansas, Michigan, North Carolina
2026-06-29
Recruiting
OHB Pediatrics Ltd.
Phase 3
165
California, Illinois, North Carolina
2026-06-23
Recruiting
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, North Carolina, Ohio, West Virginia
2026-06-23
Recruiting
A Study of ARC-02 in B-cell NHL
NCT07691606B-cell Non Hodgkin Lymphoma
DrugRituximab
Taiho Oncology, Inc.
Phase 1
140
California, Kentucky, New York, North Carolina, Virginia, Washington, Wisconsin
2026-06-22
Recruiting
Novo Nordisk A/S
Phase 2
300
Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, North Carolina, Tennessee
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Illinois, Nebraska, New York, North Carolina, Virginia
2026-06-18
Not yet open
Virtual Activities of Living for Occupational Rehabilitation
NCT07450586Stroke, Occupational Therapy, Activities of Daily Living, Rehabilitation
Barron Associates, Inc.
Not applicable
48
North Carolina
2026-06-15
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2026-06-08
By invitation
Inmagene LLC
Phase 2
400
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2026-06-05
Recruiting
AstraZeneca
Phase 2
80
Massachusetts, North Carolina
2026-06-04
Recruiting
Anifrolumab Pregnancy Study
NCT07049653Systemic Lupus Erythematosus
AstraZeneca
Observational
500
North Carolina
2026-06-04
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, South Dakota
2026-06-02
Recruiting
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
NCT07646587COPD (Chronic Obstructive Pulmonary Disease)
DrugWIN378
Windward Bio
Phase 2
105
California, Florida, Massachusetts, North Carolina, Oregon, Pennsylvania, Texas
2026-06-02
Recruiting
Philogen S.p.A.
Phase 2
180
Florida, Georgia, North Carolina, Ohio, Texas
2026-06-01
Recruiting
Dyne Therapeutics
Phase 3
90
North Carolina
2026-06
Not yet open
Study of Monochromatic X-ray Mammography System
NCT07219797Breast Imaging, Breast Cancer
Imagine Scientific, Inc.
Not applicable
52
North Carolina
2026-06
Recruiting
Novo Nordisk A/S
Phase 1
114
California, Florida, North Carolina, South Carolina, Tennessee, Texas
2026-05-29
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina
2026-05-29
Recruiting
ERX Pharmaceuticals
Phase 2
80
Kentucky, North Carolina, South Carolina
2026-05-28
Recruiting
Vericel Corporation
Phase 3
309
California, District of Columbia, Kansas, North Carolina, Texas, Virginia
2026-05-28
Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
DreaMed Diabetes
Not applicable
102
Maryland, Michigan, New York, North Carolina, Texas, Utah
2026-05-25
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1/2
32
Michigan, Minnesota, North Carolina, Tennessee, Washington
2026-05-21
Recruiting
Incyte Corporation
Phase 2
60
California, District of Columbia, Florida, Georgia, New York, North Carolina, Pennsylvania, Washington
2026-05-20
By invitation
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
NCT07393594Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
Transplant Genomics, Inc.
Observational
1,000
Arizona, California, Kansas, Michigan, New Hampshire, New Jersey, New York, North Carolina
2026-05-19
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
Tissium
Not applicable
240
California, Florida, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio
2026-05-14
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material
NCT07276711Aortic Valve Stenosis, Aortic Stenosis, Aortic Valve Disease
EmStop Inc
Not applicable
663
California, Florida, Louisiana, Michigan, North Carolina, South Dakota, Texas
2026-05-12
Recruiting
Denali Therapeutics Inc.
Phase 1
32
California, Missouri, North Carolina, Virginia
2026-05-12
Recruiting
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
Ascendis Pharma Bone Diseases A/S
Phase 3
36
Colorado, Illinois, Minnesota, Nevada, New York, North Carolina, Texas, Washington
2026-05-07
Active, closed
Bluejay Diagnostics, Inc.
Observational
450
Florida, Massachusetts, North Carolina, Tennessee, Utah
2026-05-04
Not yet open
Occlutech AFR Fontan Study
NCT07532369Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Occlutech International AB
Observational
25
Alabama, California, Colorado, Illinois, North Carolina, Texas
2026-05-01
Recruiting
Portal Therapeutics, Inc.
Observational
50
Massachusetts, New York, North Carolina, Pennsylvania, Texas
2026-04-30
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugXaluritamig
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
Descartes-08 in Autoantibody Myositis
NCT07391605Antisynthetase Syndrome
DrugDescartes-08
Cartesian Therapeutics
Phase 2
60
California, Massachusetts, North Carolina, Texas
2026-04-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Georgia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-04-23
Recruiting
Bristol-Myers Squibb
Observational
1,182
North Carolina
2026-04-21
Active, closed
Novo Nordisk A/S
Phase 3
606
Alabama, California, Florida, Illinois, Indiana, North Carolina, Pennsylvania, Rhode Island
2026-04-21
Recruiting
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
Recruiting
Oculis
Phase 2/3
160
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Virginia
2026-04-16
Recruiting
AskBio Inc
Phase 1/2
12
Arizona, California, New York, North Carolina, Pennsylvania, Texas, Virginia
2026-04-15
Recruiting
Tela Bio Inc
Not applicable
235
Florida, Kentucky, North Carolina
2026-04-10
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Recruiting
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Not yet open
Mead Johnson Nutrition
Not applicable
214
Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas
2026-04-03
Recruiting
MRM Health NV
Phase 2
204
Florida, North Carolina, Texas
2026-04-03
Recruiting
Genmab
Phase 3
544
Florida, Maryland, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2026-04-03
Recruiting
Biosense Webster, Inc.
Not applicable
566
Arkansas, California, Florida, New York, North Carolina, Texas, Utah
2026-04-02
Recruiting
Grifols Therapeutics LLC
Phase 3
40
California, Florida, New York, North Carolina, Tennessee, Texas
2026-04-02
Recruiting
Bausch Health Americas, Inc.
Phase 4
100
Arkansas, California, Florida, Kentucky, Michigan, Nevada, New York, North Carolina
2026-04-01
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Indiana, Louisiana, Michigan, North Carolina, Texas
2026-04-01
Recruiting
Aqua Medical, Inc.
Not applicable
20
Arizona, California, North Carolina
2026-04-01
Recruiting
AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation
NCT07438327Aortic Aneurysm, Aortic Aneurysm Abdominal, Aortic Aneurysm and Dissection, Aortic Aneurysm, Thoracoabdominal
Aiatella Oy
Observational
250
North Carolina, Virginia
2026-03-31
By invitation
Okami Medical ALPHA Registry
NCT07525518Arterial Bleed, Pulmonary Arteriovenous Malformation, Embolization, Hemorrhage
Okami Medical, Inc.
Observational
500
Colorado, Massachusetts, North Carolina
2026-03-31
Recruiting
Renaissance Pharma Ltd.
Phase 2/3
144
California, Colorado, Minnesota, New York, North Carolina, Pennsylvania
2026-03-30
Active, closed
Veru Inc.
Phase 2
239
Arizona, Florida, Louisiana, Maryland, Mississippi, New York, North Carolina, Texas
2026-03-26
Recruiting
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Active, closed
Eccogene
Phase 2
151
Alabama, California, Florida, Georgia, Minnesota, Nebraska, North Carolina, Ohio
2026-03-23
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
MedtronicNeuro
Not applicable
256
Alabama, Idaho, Missouri, North Carolina, Ohio, Pennsylvania, South Carolina, South Dakota
2026-03-17
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
DrugBevacizumab
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Not yet open
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
NCT06906380Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.
Observational
49
North Carolina, Texas
2026-03-15
By invitation
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
800
Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina, South Carolina, Wisconsin
2026-03-13
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
By invitation
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
NCT07197775Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Observational
500
Massachusetts, North Carolina, Texas
2026-03-11
Recruiting
Thryv Therapeutics, Inc.
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
75
Illinois, New Jersey, North Carolina, Tennessee
2026-03-04
Recruiting
TOUCH® CMC 1 New Enrollment US Study
NCT07405983Osteoarthritis Thumb, Thumb Carpometacarpal Joint Osteoarthritis
Keri Medical SA
Observational
163
Colorado, Indiana, North Carolina, Texas
2026-03-04
Recruiting
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
NCT07166133Aortic Arch Dissection, Aortic Arch Aneurysm
W.L.Gore & Associates
Not applicable
125
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, North Carolina, Pennsylvania
2026-03-02
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
DrugBendamustine
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Recruiting
PKP2-ACM Natural History Study
NCT06644742Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Genetic Diseases
Rocket Pharmaceuticals Inc.
Observational
36
Massachusetts, North Carolina
2026-03
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Recruiting
Nuvaira, Inc.
Not applicable
200
Alabama, Florida, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, Wisconsin
2026-02-24
Recruiting
Nalmefene Implant in Healthy Subjects
NCT07325279Opioid Abuse and Addiction
ReacX Pharmaceuticals, Inc.
Phase 1
24
North Carolina
2026-02-23
Recruiting
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
Elevara Medicines Limited
Phase 2
180
Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania
2026-02-18
Recruiting
Vanda Pharmaceuticals
Phase 3
300
Arizona, California, Florida, Indiana, New Hampshire, New York, North Carolina, Texas
2026-02-17
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Connecticut, North Carolina, Texas
2026-02-13
Active, closed
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Recruiting
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Recruiting
Hoffmann-La Roche
Observational
2,000
California, Indiana, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee
2026-02-09
Recruiting
Respiration From Pleth Validation
NCT07449715Respiratory Rate Monitoring
Philips Clinical & Medical Affairs Global
Observational
113
North Carolina
2026-02-06
By invitation
Cellution Biologics
Phase 4
70
North Carolina
2026-02-04
Recruiting
AbbVie
Phase 2
200
California, Florida, Illinois, Kansas, Minnesota, North Carolina, Ohio, Pennsylvania
2026-02-04
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Recruiting
Peptilogics
Phase 2/3
240
Florida, Louisiana, Maryland, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2026-02-03
Recruiting
Bristol-Myers Squibb
Phase 1/2
240
Michigan, New York, North Carolina, Ohio, Tennessee
2026-02-03
Recruiting
OsteoRemedies, LLC
Phase 2
60
Michigan, North Carolina
2026-02-01
Not yet open
SynchroHealth LLC
Not applicable
39
North Carolina
2026-02
Active, closed
Praxis Precision Medicines
Phase 3
300
Florida, New Jersey, New York, North Carolina, Texas
2026-01-29
Recruiting
Dentsply Sirona Implants and Consumables
Not applicable
90
California, New Jersey, North Carolina, Texas
2026-01-29
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
DrugTAK-861
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Recruiting
Tempus AI
Observational
550
Iowa, Maryland, Missouri, Nevada, New York, North Carolina, North Dakota, Ohio
2026-01-27
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-26
Recruiting
Drug-Drug Interaction Study of ABP-671 in Gout Patients
NCT07367971Gout Chronic, Gout, DDI (Drug-Drug Interaction)
DrugsABP-671·Allopurinol
Atom Therapeutics Co., Ltd
Phase 1
20
North Carolina
2026-01-23
Recruiting
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
DualityBio Inc.
Phase 1/2
127
Florida, Michigan, North Carolina, Ohio
2026-01-20
Recruiting
Kahr Bio Australia Pty Ltd
Phase 2
90
Colorado, Florida, North Carolina, Pennsylvania, Texas
2026-01-16
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
Royal Ancient Oats™ Study
NCT07371598Healthy Participants, Healthy Glucose
Standard Process Inc.
Not applicable
38
North Carolina
2026-01-13
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Alabama, Iowa, Kansas, North Carolina, South Carolina, Utah
2026-01-13
Recruiting
AstraZeneca
Phase 1/2
84
Illinois, New York, North Carolina, Oregon, Texas
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington
2026-01-09
By invitation
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668Colorectal Cancer, Stoma - Ileostomy
SafeHeal Inc
Not applicable
108
California, Florida, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-08
Recruiting
Amicus Therapeutics
Phase 3
8
Georgia, Minnesota, North Carolina, Ohio, Pennsylvania, Virginia
2026-01-08
Recruiting
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
Arizona, California, Florida, Kansas, New York, North Carolina, Ohio, Oregon
2026-01-07
Recruiting
Disc Medicine, Inc
Phase 1
24
Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio
2026-01-06
Recruiting
TransMedics
Not applicable
655
California, Florida, Massachusetts, New York, North Carolina, Texas
2026-01
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
argenx
Observational
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
Merida Biosciences
Phase 1
100
California, Florida, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania, Texas
2025-12-19
Recruiting
argenx
Phase 2
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Recruiting
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Recruiting
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
TORL Biotherapeutics, LLC
Phase 1/2
60
California, Minnesota, New York, North Carolina
2025-12-10
Recruiting
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
NCT07172893Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
HealthTech Wound Care
Phase 4
150
Florida, Michigan, North Carolina, Ohio, Texas, Virginia
2025-12-10
Recruiting
Protara Therapeutics
Phase 2/3
129
Colorado, Florida, Illinois, Nebraska, New York, North Carolina, Ohio, Texas
2025-12-10
By invitation
NuvOx LLC
Observational
40
Arizona, Connecticut, Missouri, North Carolina
2025-12-08
Recruiting
Comparative Study of Ziplyft Treatment vs. Traditional Blepharoplasty for Upper Eyelid Rejuvenation
NCT07250139Dermatochalasis of Upper Eyelid, Ptosis, Eyelid, Blepharoplasty
Osheru Inc.
Not applicable
50
North Carolina
2025-12-08
Active, closed
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
ENA Respiratory Pty Ltd
Phase 2
1,100
Maryland, North Carolina
2025-12-04
Recruiting
Sangamo Therapeutics
Phase 1/2
27
Arizona, Arkansas, California, Maryland, Massachusetts, New Hampshire, New York, North Carolina
2025-12-04
Active, closed
Arthrosi Therapeutics
Phase 2
15
Florida, Mississippi, North Carolina, Pennsylvania, Texas, Washington
2025-12-03
Recruiting
Conjupro Biotherapeutics, Inc.
Phase 1
270
North Carolina, Texas, Virginia
2025-12-02
Active, closed
Hanmi Pharmaceutical Company Limited
Phase 2
267
California, Illinois, Iowa, North Carolina, South Carolina, Tennessee, Texas
2025-12-02
Recruiting
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Recruiting
Providence Medical Technology, Inc.
Not applicable
250
Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah
2025-12-01
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899Catecholaminergic Polymorphic Ventricular Tachycardia
DrugCRD-4730
Cardurion Pharmaceuticals, Inc.
Phase 2
12
California, North Carolina, Texas, Utah, Wisconsin
2025-12-01
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Recruiting
Pfizer
Phase 1/2
138
California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Ohio
2025-12-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
AstraZeneca
Phase 1
40
North Carolina, Texas, Virginia
2025-11-25
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Active, closed
Biohaven Therapeutics Ltd.
Phase 2
150
California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota
2025-11-24
Recruiting
Assessment of AI Program 'DRISTi' as a Screening Tool
NCT07222293Diabetic Retinopathy (DR)
Artelus AI
Observational
900
North Carolina
2025-11-23
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
DrugDarolutamide
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Recruiting
AbbVie
Phase 1
220
California, Illinois, Michigan, North Carolina, Texas
2025-11-20
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
DrugPembrolizumab
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
By invitation
MoonLake Immunotherapeutics AG
Phase 3
1,560
Arizona, Arkansas, California, Florida, North Carolina, Ohio, Pennsylvania, Tennessee
2025-11-13
Active, closed
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
By invitation
Impact of Anatomy-Based Cochlear Implant Programming on Early Performance
NCT06734039Hearing Loss, Unilateral, Cochlear Implants, Hearing Loss, Sensorineural, Single-Sided Deafness (SSD)
Med-El Corporation
Not applicable
50
Iowa, Kansas, North Carolina, Oregon, Pennsylvania
2025-11-10
Recruiting
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
NCT06888193Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 1
20
California, Florida, Massachusetts, North Carolina, Wisconsin
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Recruiting
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
Recruiting
Ingenia Therapeutics INC
Phase 1/2
94
California, Florida, North Carolina
2025-10-30
Recruiting
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
California, Florida, Georgia, Louisiana, Nevada, North Carolina
2025-10-29
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Active, closed
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Active, closed
Thryv Therapeutics, Inc.
Observational
200
North Carolina
2025-10-27
Recruiting
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
NCT06631638Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congential Hip Dysplasia
DePuy Orthopaedics
Not applicable
118
Florida, North Carolina
2025-10-24
Recruiting
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
ITF Therapeutics LLC
Observational
300
Arkansas, District of Columbia, Illinois, Massachusetts, New York, North Carolina, Oregon, Washington
2025-10-23
Recruiting
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
Pivotal Study of the Velocity™ pAVF System
NCT07153939Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Venova Medical
Not applicable
126
Alabama, California, Florida, New York, North Carolina, South Carolina, Texas
2025-10-21
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Recruiting
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
NCT07229430Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
CLASSYS Inc.
Not applicable
273
California, North Carolina, Tennessee, Washington
2025-10-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
25
Massachusetts, New York, North Carolina
2025-10-16
Recruiting
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
Long-Term Stability of the Glide Control Strategy
NCT07222085Upper Limb Amputation Above Elbow, Upper Limb Amputation Below Elbow
Infinite Biomedical Technologies
Not applicable
12
Maryland, Massachusetts, North Carolina, South Carolina, Virginia
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Active, closed
Eli Lilly and Company
Phase 2
100
Arizona, California, Florida, Iowa, Missouri, North Carolina, Oklahoma, South Carolina
2025-10-13
Recruiting
Z1 Hip System: Post-Market Clinical Follow Up Study
NCT07104279Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
Zimmer Biomet
Observational
300
North Carolina, Ohio, Oregon, Virginia
2025-10-13
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 2
60
California, Illinois, Maryland, Missouri, North Carolina, Ohio, Texas
2025-10-13
Recruiting
Sanofi
Phase 1/2
104
Arizona, California, Florida, Georgia, Illinois, Maryland, Nevada, North Carolina
2025-10-09
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Recruiting
CatalYm GmbH
Phase 2
131
Alabama, California, New York, North Carolina
2025-10-07
Active, closed
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
DrugSparsentan
Travere Therapeutics, Inc.
Phase 4
20
Alabama, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
2025-10-07
Recruiting
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
Philips Clinical & Medical Affairs Global
Observational
205
Massachusetts, North Carolina
2025-10-02
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Recruiting
ImmunityBio, Inc.
Phase 3
507
Arkansas, California, Florida, Georgia, Missouri, North Carolina, Ohio, South Carolina
2025-10-01
Recruiting
Incyte Corporation
Phase 1
120
Arizona, California, Colorado, Florida, Illinois, Maryland, New York, North Carolina
2025-10-01
Recruiting
Vanda Pharmaceuticals
Phase 2
160
California, Massachusetts, North Carolina, Tennessee, Virginia
2025-10
Recruiting
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
California, Florida, Illinois, Kansas, New York, North Carolina, Pennsylvania, Washington
2025-09-30
Recruiting
FemPulse Corporation
Not applicable
151
California, Florida, Illinois, Kentucky, Maryland, Minnesota, Nebraska, North Carolina
2025-09-30
Recruiting
Nuvig Therapeutics, Inc.
Phase 2
30
District of Columbia, Massachusetts, North Carolina
2025-09-30
Recruiting
Synaptrix, Inc.
Not applicable
120
Alabama, New York, North Carolina, Oregon, Washington
2025-09-30
Recruiting
Genentech, Inc.
Phase 2
224
California, Colorado, Florida, Illinois, New York, North Carolina, Utah
2025-09-29
Active, closed
SPHERE Per-AF Post-Approval Study
NCT06858306Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania
2025-09-25
Recruiting
Novartis Pharmaceuticals
Phase 1
20
California, Florida, Illinois, New York, North Carolina, Ohio, Oregon, Pennsylvania
2025-09-24
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
Sanofi
Phase 4
218
Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania
2025-09-22
Recruiting
Biometry Inc
Observational
160
California, Florida, Georgia, Maine, Maryland, Nebraska, North Carolina, Ohio
2025-09-17
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Active, closed
Beacon Therapeutics
Phase 2
10
Florida, North Carolina, Ohio, Oregon, Texas
2025-09-10
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Massachusetts, North Carolina
2025-09-04
Recruiting
Deciphera Pharmaceuticals, LLC
Observational
100
North Carolina
2025-09-03
Recruiting
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
NCT06919354Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
GentiBio, Inc
Phase 1
16
California, Florida, Massachusetts, New York, North Carolina
2025-09-03
Recruiting
Opus Genetics, Inc
Phase 3
580
Arizona, California, Florida, Illinois, Kansas, Massachusetts, North Carolina, Pennsylvania
2025-09-02
Not yet open
SNAPS Breast Cancer Patient Study Breast Cancer Patients
NCT05370300Breast Cancer, Breast Cancer Female
Immunis.AI
Observational
500
North Carolina
2025-09-01
Active, closed
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
NCT07120945Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis
Medtronic - MITG
Not applicable
70
Florida, North Carolina, Pennsylvania, Washington
2025-08-28
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
By invitation
Harmony Biosciences Management, Inc.
Phase 3
150
North Carolina
2025-08-20
Recruiting
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Active, closed
Aleniglipron Phase 2 Body Composition Study
NCT07169942Obesity, Overweight, or Chronic Weight Management
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
71
Arizona, Illinois, Minnesota, Missouri, New York, North Carolina, Oklahoma, South Carolina
2025-08-15
Recruiting
mHealth Systems Inc.
Not applicable
150
North Carolina, South Carolina
2025-08-15
Recruiting
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
Kedrion S.p.A.
Phase 3
40
California, New York, North Carolina
2025-08-13
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Active, closed
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Recruiting
GlaxoSmithKline
Phase 3
420
California, New York, North Carolina, Ohio
2025-08-11
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
North Carolina
2025-08-11
Recruiting
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
FiberLocker® System Augmentation of Rotator Cuff Repairs
NCT06918041Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder
ZuriMED Technologies Inc.
Not applicable
60
Illinois, Maryland, North Carolina, Oregon
2025-08-05
Active, closed
Ensoma
Phase 1/2
15
California, Florida, Massachusetts, Minnesota, New York, North Carolina, Utah
2025-08-05
Recruiting
Whole Endo
Observational
100
North Carolina
2025-08-01
Recruiting
Eko Devices, Inc.
Observational
1,513
California, North Carolina
2025-08-01
Recruiting
CatalYm GmbH
Phase 2
107
Alabama, California, Connecticut, Florida, New York, North Carolina, South Carolina
2025-08-01
Recruiting
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
California, Illinois, Indiana, Nevada, North Carolina, Pennsylvania, Texas, Wisconsin
2025-07-30
Recruiting
Merit Medical Systems, Inc.
Observational
100
District of Columbia, Florida, North Carolina, Pennsylvania, Texas, Virginia
2025-07-28
Recruiting
Tela Bio Inc
Not applicable
173
Alabama, Colorado, Kentucky, North Carolina, Texas
2025-07-25
Not yet open
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Recruiting
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Active, closed
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Recruiting
Sonoma Biotherapeutics, Inc.
Observational
36
California, Colorado, Illinois, Massachusetts, Minnesota, North Carolina, Texas
2025-07-22
Active, closed
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
California, New York, North Carolina, Pennsylvania, Tennessee
2025-07-20
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Recruiting
Daiichi Sankyo
Phase 1
76
California, Georgia, Nevada, North Carolina, Ohio, Tennessee
2025-07-17
Recruiting
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
NCT07017933Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
3ive Labs
Not applicable
124
Florida, Michigan, North Carolina, Ohio
2025-07-16
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Recruiting
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Recruiting
Uro-1 Medical
Not applicable
200
New York, North Carolina, South Carolina
2025-07-07
Active, closed
Upstream Bio Inc.
Phase 2
666
California, Florida, Georgia, Illinois, Maryland, Minnesota, North Carolina, South Carolina
2025-07-02
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
AstraZeneca
Observational
442
North Carolina
2025-07-01
Recruiting
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Active, closed
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
Boston Scientific Corporation
Observational
238
Arizona, Florida, Indiana, North Carolina
2025-06-30
Active, closed
LifeNet Health
Not applicable
120
Arizona, California, Florida, Illinois, North Carolina, Texas, Virginia
2025-06-26
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina
2025-06-25
Recruiting
Galvanize Therapeutics, Inc.
Observational
1,000
Arizona, California, Florida, New York, North Carolina, Pennsylvania, South Carolina, Texas
2025-06-23
Active, closed
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Recruiting
Inmagene LLC
Phase 2
405
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2025-06-17
Recruiting
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
Recruiting
GlaxoSmithKline
Phase 1/2
451
California, Colorado, New York, North Carolina, Texas, Washington, Wisconsin
2025-06-11
Recruiting
Cerus Endovascular, Inc.
Not applicable
250
Illinois, Kansas, New York, North Carolina, Pennsylvania, South Carolina, Washington
2025-06-10
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington
2025-06-10
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
California, Florida, Georgia, Illinois, Louisiana, Nevada, New York, North Carolina
2025-06-10
Active, closed
Digital Health Navigation Solutions, Inc
Not applicable
6,500
Georgia, North Carolina
2025-06-09
Recruiting
HLA Demographics Study in Adults With Type 1 Diabetes
NCT06860516Diabetes Mellitus, Type I
GentiBio, Inc
Observational
200
California, Florida, Massachusetts, New York, North Carolina
2025-06-06
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
Neurocrine Biosciences
Phase 3
200
California, Colorado, Connecticut, Florida, Maryland, New York, North Carolina, Pennsylvania
2025-05-30
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Recruiting
W.L.Gore & Associates
Observational
158
California, Florida, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2025-05-30
Active, closed
Arvinas Inc.
Phase 1/2
76
Arizona, Connecticut, Florida, Indiana, Michigan, New York, North Carolina, Ohio
2025-05-29
Recruiting
STimulation to Activate RespIration
NCT06832306ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
Lungpacer Medical Inc.
Not applicable
30
California, Louisiana, North Carolina, Ohio, Pennsylvania, South Carolina
2025-05-28
Recruiting
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Phase 1
12
Maryland, North Carolina, Utah
2025-05-27
Recruiting
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Recruiting
Coologics, Inc
Not applicable
55
Florida, Georgia, Idaho, Illinois, North Carolina, Tennessee, Texas
2025-05-22
Recruiting
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
NCT06680752Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
DrugsFludarabine·Cyclophosphamide
ARCE Therapeutics, Inc.
Phase 1/2
49
North Carolina, Texas
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Ohio, Tennessee, Texas, Virginia
2025-05-19
Recruiting
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Recruiting
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06660342Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
DrugVonoprazan
Phathom Pharmaceuticals, Inc.
Observational
728
North Carolina
2025-05-15
Recruiting
Pfizer
Phase 1
15
California, North Carolina
2025-05-13
Active, closed
Eli Lilly and Company
Phase 3
465
California, Colorado, Florida, Iowa, Minnesota, Missouri, Nevada, North Carolina
2025-05-12
Recruiting
Samaritan Biologics
Not applicable
170
North Carolina
2025-05-09
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases
HepaRegeniX GmbH
Phase 1/2
80
Maryland, Minnesota, North Carolina, Ohio
2025-05-06
Recruiting
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Active, closed
Hoffmann-La Roche
Phase 2
285
Alabama, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio
2025-05-05
Recruiting
AstraZeneca
Phase 1
72
Alabama, California, Iowa, Nebraska, North Carolina
2025-05-01
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
Auron Therapeutics, Inc.
Phase 1
69
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2025-05-01
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
OpiAID
Not applicable
420
North Carolina
2025-05-01
Recruiting
Takeda
Observational
30
California, Connecticut, Florida, Hawaii, Illinois, Kansas, North Carolina
2025-04-29
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, New York, North Carolina
2025-04-23
Recruiting
Endomagnetics Ltd.
Observational
184
North Carolina, Virginia
2025-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
California, North Carolina, Pennsylvania, Texas
2025-04-22
Recruiting
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Recruiting
Fertilo In Vitro Research Study and Trial
NCT06858111In Vitro Maturation of Oocytes
Gameto, Inc.
Phase 3
500
California, Florida, Maryland, New York, North Carolina, Texas, Utah
2025-04-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
168
California, North Carolina, Pennsylvania, Wisconsin
2025-04-09
Recruiting
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
NCT06708897CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
Lomond Therapeutics Holdings, Inc.
Phase 1
84
Kentucky, North Carolina, Ohio, Texas
2025-04-08
Active, closed
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Trellis Bioscience LLC
Phase 2
60
Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas
2025-04-08
Active, closed
UCB Biopharma SRL
Phase 3
43
California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio, Texas
2025-04-07
Recruiting
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Not yet open
BioMimetix JV, LLC
Phase 1/2
27
North Carolina
2025-04-01
Recruiting
Nimbus Wadjet, Inc.
Phase 1/2
134
California, Illinois, Kentucky, New York, North Carolina, Ohio, Rhode Island, South Carolina
2025-03-31
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
DrugsMIRV·Mirvetuximab Soravtansine·Adriamycin·Topotecan
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Recruiting
MagDI U.S. Registry
NCT06928545Anastomosis, Surgical, Internal Hernia, Bowel Obstruction
GT Metabolic Solutions, Inc.
Observational
106
California, Florida, Kentucky, Louisiana, North Carolina, Washington
2025-03-28
Recruiting
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
Phase 2
60
North Carolina
2025-03-12
Recruiting
Iovance Biotherapeutics, Inc.
Phase 1/2
42
Colorado, North Carolina, Tennessee
2025-03-11
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Recruiting
APOL1 Genotyping CTA Clinical Performance Study
NCT06839833APOL1-mediated Kidney Disease
Almac Diagnostic Services LLC
Not applicable
2,000
North Carolina
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
DrugsCisplatin/Carboplatin·MFOLFIRINOX·MFOLFOX6·Midazolam
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Recruiting
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Recruiting
GlaxoSmithKline
Phase 1/2
305
California, Colorado, New York, North Carolina, Ohio
2025-03-04
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Active, closed
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
DrugALN-4324
Alnylam Pharmaceuticals
Phase 1/2
105
California, District of Columbia, Florida, New Jersey, North Carolina, Texas
2025-03-03
Active, closed
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Active, closed
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Maryland, Missouri, North Carolina, Pennsylvania, Virginia
2025-02-28
Active, closed
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Recruiting
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2
200
Minnesota, North Carolina, Pennsylvania
2025-02-25
Recruiting
Breathe BioMedical Inc
Observational
5,175
District of Columbia, Florida, North Carolina, Pennsylvania
2025-02-25
Recruiting
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Arkansas, Florida, Illinois, North Carolina, Pennsylvania, Texas
2025-02-21
By invitation
Integrity Orthopaedics, Inc.
Observational
100
North Carolina, Texas
2025-02-20
Recruiting
Bristol-Myers Squibb
Phase 1/2
413
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Recruiting
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1/2
280
California, North Carolina, Oklahoma, Texas
2025-02-17
Recruiting
March Biosciences Inc
Phase 2
46
California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina
2025-02-15
Recruiting
Bantam Pharmaceuticals
Phase 1
24
North Carolina, Texas
2025-02-14
Recruiting
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Alabama, California, Colorado, Illinois, Indiana, Iowa, New York, North Carolina
2025-02-10
Recruiting
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
North Carolina, Ohio, Pennsylvania
2025-02-04
Recruiting
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Colorado, District of Columbia, Florida, Illinois, Massachusetts, North Carolina, Ohio, Pennsylvania
2025-02-01
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Recruiting
Tissue Repair Gel in Venous Leg Ulcers (US)
NCT06707090Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
DrugGlucoprime
TR Therapeutics
Phase 3
312
Arizona, California, Florida, Illinois, Louisiana, Mississippi, New York, North Carolina
2025-01-28
Active, closed
AbbVie
Phase 1
4
California, Montana, North Carolina, Texas
2025-01-27
Active, closed
Orthofix PhysioStim PEMF Ankle Fusion Retrospective
NCT07282067Ankle Fusion, Hindfoot Arthrodesis, Ankle Arthrodesis, Tibiotalar Arthrodesis
Orthofix Inc.
Observational
200
Arizona, California, Iowa, Maryland, North Carolina, Texas
2025-01-23
Recruiting
US National TOP Registry
NCT06513091Lung Transplant
TransMedics
Observational
10,000
Arizona, California, Minnesota, North Carolina, Texas, Wisconsin
2025-01-23
Active, closed
AbbVie
Phase 1
21
North Carolina, Oregon, Texas, Utah, Virginia
2025-01-16
By invitation
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
NCT07217977Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Qbtech AB
Observational
175
Alabama, California, Florida, North Carolina, Texas
2025-01-15
Active, closed
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
NCT07701161Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Neurogen Biomarking LLC
Observational
1,000
Illinois, Michigan, North Carolina
2025-01-13
Recruiting
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Recruiting
VistaGen Therapeutics, Inc.
Phase 2
60
California, Florida, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Texas
2025-01-09
Active, closed
Palvella Therapeutics, Inc.
Phase 2
15
California, Colorado, Maryland, Minnesota, North Carolina, Ohio, Pennsylvania, Utah
2024-12-20
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
California, Connecticut, Florida, New York, North Carolina, Wisconsin
2024-12-18
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Alabama, Florida, Georgia, Illinois, Iowa, North Carolina, Pennsylvania, Texas
2024-12-17
Active, closed
AbbVie
Phase 2
185
California, Florida, Georgia, Mississippi, North Carolina, Texas
2024-12-13
Active, closed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432Alzheimer Disease, Early Onset
ProMis Neurosciences, Inc
Phase 1
144
California, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2024-12-13
Recruiting
Boehringer Ingelheim
Phase 2
80
Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas
2024-12-11
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Recruiting
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525Primary Sjögren Syndrome
Resolve Therapeutics
Phase 2
106
California, Florida, Illinois, Iowa, Massachusetts, New Mexico, North Carolina, Pennsylvania
2024-12-01
Active, closed
Hemanext
Not applicable
24
North Carolina
2024-11-29
Active, closed
SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization
NCT06550024Osteo Arthritis Knee, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
CrannMed
Not applicable
89
Alabama, California, Florida, North Carolina, Virginia
2024-11-28
Recruiting
Idorsia Pharmaceuticals Ltd.
Observational
785
North Carolina
2024-11-21
Recruiting
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
Peerbridge Health, Inc
Observational
2,000
California, Michigan, New Jersey, New York, North Carolina, Texas
2024-11-21
Recruiting
Syntrix Biosystems, Inc.
Phase 2
53
California, Michigan, Minnesota, North Carolina, Wisconsin
2024-11-18
Recruiting
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
NCT06603246Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Genentech, Inc.
Phase 1
128
Alabama, California, Kansas, North Carolina, Pennsylvania, Texas
2024-11-18
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania
2024-11-18
Recruiting
Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
NCT06681428Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Tides Medical
Not applicable
240
California, Florida, North Carolina, Ohio, Virginia
2024-11-14
Recruiting
Neurona Therapeutics
Phase 1/2
10
Arkansas, California, Colorado, Illinois, Iowa, New York, North Carolina, Oregon
2024-11-14
Recruiting
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
NCT06462729Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Locate Bio Pty Ltd
Phase 1/2
40
Indiana, North Carolina, Tennessee
2024-11-12
Active, closed
Bluejay Diagnostics, Inc.
Observational
700
Florida, Massachusetts, North Carolina, Tennessee, Utah
2024-11-12
By invitation
Xeltis Hemodialysis Access Graft (aXess) US Study
NCT06494631End Stage Renal Disease
Xeltis
Not applicable
140
Arizona, Florida, Massachusetts, Mississippi, North Carolina, Texas
2024-11-11
Active, closed
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
By invitation
Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)
NCT06311331Avascular Necrosis of the Talus, Talar Osteochondral Defect of Ankle, Talar Dysfunction
Restor3D
Observational
50
North Carolina
2024-11-06
Active, closed
Takeda
Phase 3
53
California, Colorado, Florida, Georgia, Illinois, Louisiana, New York, North Carolina
2024-11-04
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas
2024-11-04
Recruiting
Renovo Concepts, Inc.
Not applicable
11
New York, North Carolina, West Virginia
2024-11-01
Recruiting
Eli Lilly and Company
Phase 1
128
California, Florida, Georgia, Michigan, New Jersey, North Carolina
2024-10-29
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
320
California, Florida, Massachusetts, Nevada, New Jersey, North Carolina, Texas
2024-10-22
Active, closed
Amgen
Phase 3
19
Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas
2024-10-22
Active, closed
Abcuro, Inc.
Phase 2/3
270
Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2024-10-21
Active, closed
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Active, closed
Amgen
Phase 1
21
California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma
2024-10-16
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
960
Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, North Carolina
2024-10-15
Active, closed
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Recruiting
Xencor, Inc.
Phase 1/2
270
Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio
2024-10-10
Active, closed
Sonoma Biotherapeutics, Inc.
Phase 1
24
Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas
2024-10-09
Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Recruiting
DermaSensor Postmarket Surveillance Study
NCT06666790Melanoma, Skin
DermaSensor, Inc.
Not applicable
396
Florida, North Carolina
2024-10-08
Recruiting
GlaxoSmithKline
Observational
300
Maryland, North Carolina, Ohio, Tennessee
2024-10-04
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-03
Recruiting
Abbott Nutrition
Not applicable
96
Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas
2024-10-01
By invitation
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
California, Connecticut, Florida, Illinois, New York, North Carolina
2024-09-26
Recruiting
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Active, closed
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
50
Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington
2024-09-23
Recruiting
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Recruiting
GlaxoSmithKline
Phase 3
440
California, Florida, Missouri, New York, North Carolina, Pennsylvania, Texas, Utah
2024-09-11
Active, closed
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
NCT05839730Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
105
Florida, Illinois, Kansas, North Carolina, Oklahoma, Texas, Vermont
2024-09-11
Recruiting
RevCore for In Stent Thrombosis
NCT06394739In-stent Thrombosis
Inari Medical
Observational
100
Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania
2024-09-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Barron Associates, Inc.
Not applicable
60
North Carolina
2024-09-04
Active, closed
Cullinan Therapeutics Inc.
Phase 1
30
Arizona, Florida, Minnesota, New York, North Carolina, Texas
2024-09-03
Recruiting
DualityBio Inc.
Phase 1/2
360
California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah
2024-09-03
Active, closed
argenx
Phase 2
33
Alabama, California, Illinois, Nebraska, North Carolina, Ohio, Virginia, Washington
2024-08-30
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina
2024-08-28
Active, closed
AstraZeneca
Phase 2
194
California, North Carolina
2024-08-27
Recruiting
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Recruiting
Opna Bio LLC
Phase 1
130
Arizona, California, Georgia, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-08-22
Recruiting
Octapharma
Phase 3
120
California, Florida, Massachusetts, North Carolina, Ohio, Oklahoma, Texas
2024-08-21
Active, closed
Janssen Research & Development, LLC
Phase 2
43
California, Iowa, New York, North Carolina
2024-08-20
Recruiting
Innova Vascular, Inc.
Not applicable
107
Alabama, Arizona, California, District of Columbia, Florida, Illinois, New York, North Carolina
2024-08-19
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
California, Maryland, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas
2024-08-19
Recruiting
Eli Lilly and Company
Phase 1
48
Florida, Georgia, Massachusetts, New Jersey, North Carolina
2024-08-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, New York, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Rows per page Showing 1–500 of 1082
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/north-carolina

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,082 of those studies with a site in North Carolina.

How many clinical trials are recruiting in North Carolina?

595 of the 1,082 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 28 have not yet opened recruitment, 411 are active but closed to new participants, and 48 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (North Carolina), 1,082 studies
PhaseStudiesRecruitingShare
Phase 32059618.9%
Phase 118911517.5%
Phase 21879517.3%
Observational17110015.8%
Not applicable1457513.4%
Phase 1/21257811.6%
Phase 2/331182.9%
Phase 427172.5%
Early Phase 1210.2%

Most active sponsors

Lead sponsors with the most studies (North Carolina)
Lead sponsorStudiesRecruiting
AbbVie3516
AstraZeneca3218
Novartis Pharmaceuticals2311
Janssen Research & Development, LLC228
Hoffmann-La Roche183
GlaxoSmithKline1711
Merck Sharp & Dohme LLC148
Pfizer1410
Sanofi144
Amgen133
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.